EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis

Olga Halle iD, Simon Y Graeber iD, Julia Kontsendorn, Claudia Kessemeier, Jan-Niklas Falke, Jannik Schwabe, Katharina Schütz iD, Sophia T Pallenberg, Rebecca Dalferth, Ruth Grychtol iD, Felix C Ringshausen iD, Mirjam Stahl iD und 24 weitere

European Respiratory Journal · 2025

DOI: 10.1183/13993003.00150-2025 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Olga Halle und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Chloride Channel Agonists, Cystic Fibrosis, Inflammation, Lung. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Vienna Science and Technology Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The triple cystic fibrosis transmembrane conductance regulator modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI) rapidly improves airway and systemic inflammation in people with cystic fibrosis. However, longitudinal effects on systemic inflammation and their relationship to lung function remain unknown.

Methods

In this prospective, observational, multicentre study, we analysed peripheral blood neutrophil counts, C-reactive protein (CRP) and six pro-inflammatory serum cytokines in a cohort of 198 people with cystic fibrosis aged ≥6 years at baseline and follow-up visits 3, 12 and 24 months after initiation of ETI, compared to 74 age-matched healthy control participants.

Results

Neutrophil counts and CRP, granulocyte colony-stimulating factor, interleukin (IL)-1β, IL-6 and IL-8 were reduced to 71%, 40%, 41%, 63%, 46% and 81% of median baseline values, respectively, after 3 months of therapy (all p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chloride Channel AgonistsCystic FibrosisInflammationLungAdolescentAdultChildFemaleHumansMaleYoung AdultAminophenolsBenzodioxolesC-Reactive ProteinCase-Control StudiesCystic Fibrosis Transmembrane Conductance RegulatorCytokinesDrug CombinationsIndolesProspective StudiesPyrazolesPyridinesPyrrolidinesQuinolones

Substanzen

AminophenolsBenzodioxolesC-Reactive ProteinChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorCytokinesDrug Combinationselexacaftorelexacaftor, ivacaftor, tezacaftor drug combinationIndoles

Autor:innen und Institutionen

  • Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.
  • German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Hannover, Germany.
  • O. Halle and S.Y. Graeber contributed equally as first authors.
  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • German Center for Lung Research (DZL), associated partner site Berlin, Berlin, Germany.
  • German Center for Child and Adolescent Health (DZKJ), partner site Berlin, Berlin, Germany.

ORCID-Profile: Olga Halle, Simon Y Graeber, Katharina Schütz, Ruth Grychtol, Felix C Ringshausen, Mirjam Stahl, Stephanie Thee, Jobst F Roehmel, Julia Duerr, Markus Weckmann, Burkhard Tümmler, Olaf Sommerburg, Marcus A Mall, Anna-Maria Dittrich

Förderung

  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung
  • Vienna Science and Technology Fund
  • Excellence cluster EXC 2155 ‘RESIST’

Zitieren

APA

Halle, O., Graeber, S. Y., Kontsendorn, J., Kessemeier, C., Falke, J. N., Schwabe, J., Schütz, K., Pallenberg, S. T., Dalferth, R., Grychtol, R., Ringshausen, F. C., Stahl, M., Thee, S., Roehmel, J. F., Syunyaeva, Z., Duerr, J., Chung, J., Hirtz, S., Uselmann, T., …, & Dittrich, A. M. (2025). Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. European Respiratory Journal. https://doi.org/10.1183/13993003.00150-2025

Vancouver

Halle O, Graeber SY, Kontsendorn J, Kessemeier C, Falke JN, Schwabe J, et al. Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. European Respiratory Journal. 2025. doi:10.1183/13993003.00150-2025

BibTeX
@article{Halle2025,
  author = {Halle, Olga and Graeber, Simon Y and Kontsendorn, Julia and Kessemeier, Claudia and Falke, Jan-Niklas and Schwabe, Jannik and Schütz, Katharina and Pallenberg, Sophia T and Dalferth, Rebecca and Grychtol, Ruth and Ringshausen, Felix C and Stahl, Mirjam and Thee, Stephanie and Roehmel, Jobst F and Syunyaeva, Zulfiya and Duerr, Julia and Chung, Jaehi and Hirtz, Stephanie and Uselmann, Tatjana and Kühbandner, Iris and Rückes-Nilges, Claudia and Bagheri-Pothoff, Azadeh and Barth, Sandra and Schaub, Bianca and Brinkmann, Folke and Weber, Stefanie and van Koningsbruggen-Rietschel, Silke and Abdo, Mustafa and Weckmann, Markus and Widder, Stefanie and Hansen, Gesine and Tümmler, Burkhard and Sommerburg, Olaf and Naehrlich, Lutz and Mall, Marcus A and Dittrich, Anna-Maria},
  title = {Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis},
  journal = {European Respiratory Journal},
  year = {2025},
  doi = {10.1183/13993003.00150-2025}
}
Kostenlos starten →